Preoperative CEA and Colorectal Cancer Survival
Author Information
Author(s): MAS Chapman, D Buckley, DB Henson, NC Armitage
Primary Institution: University Hospital, Queens Medical Centre, Nottingham, UK
Hypothesis
The study investigates the value of preoperative carcinoembryonic antigen (CEA) in predicting tumour factors and long-term survival in colorectal cancer patients.
Conclusion
A raised preoperative serum CEA is associated with advanced tumour stage and poor long-term survival, but is not a useful predictor of survival once tumour stage is known.
Supporting Evidence
- Patients with an elevated CEA had a 5-year survival of 39%.
- This increased to 57% if the CEA was normal.
- The proportion of patients with a raised CEA increased with a more advanced tumour stage.
- Once stage was controlled for, CEA was not a predictor of survival.
Takeaway
If a patient has high levels of a certain protein before surgery for colon cancer, it might mean their cancer is more advanced and they may not live as long, but knowing this doesn't help predict how long they will live once the cancer stage is known.
Methodology
The study measured preoperative serum CEA levels in 277 patients undergoing colorectal cancer surgery and followed them for a minimum of 5 years.
Limitations
The study does not account for the potential impact of adjuvant chemotherapy on survival outcomes.
Participant Demographics
Median age of participants was 67 years, with a range of 40-87 years.
Statistical Information
P-Value
0.001
Confidence Interval
95% confidence intervals 1.4-2.9
Statistical Significance
p<0.000001
Want to read the original?
Access the complete publication on the publisher's website